摘要
目的:回顾PI3K / AKT / mTOR信号通路的作用以及靶向PI3Ks针对各种疾病(如恶性,自身免疫,炎症,心血管,神经系统疾病等)的当前和未来前景,特别强调炎性疾病和相关的细胞反应。 背景:最近的发现已经将磷酸肌醇-3-激酶(PI3Ks)公布为新的治疗靶点,也被认为参与炎症和各种其他疾病的复杂病理生理学。通过调节各种免疫细胞的生长,发育和增殖,并且因此影响参与这些表现的各种细胞因子和其它炎症介质的释放,它们被认可参与炎性细胞反应。最近有关这种途径与这些疾病有关的文献被强调,希望是PI3K抑制剂在市场上作为治疗选择的进展。 结果:Idelalisib进入癌症市场,PI3K / AKT信号也作为各种疾病,特别是炎症的研究对象,具有重要意义。基于药理学,遗传学和临床资料,PI3K / AKT信号可以被指定为治疗的突出靶点。 结论:进一步探索这一途径也可能揭示其参与这些障碍,这可能进一步有助于开发新的治疗方法,并可能成为未来实验和临床药理学领域创新的脑波。
关键词: 磷酸肌醇-3-激酶(PI3Ks),PI3K抑制剂,炎症,免疫细胞,免疫细胞信号传导,炎性疾病。
Current Drug Targets
Title:Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Volume: 18 Issue: 14
关键词: 磷酸肌醇-3-激酶(PI3Ks),PI3K抑制剂,炎症,免疫细胞,免疫细胞信号传导,炎性疾病。
摘要: Objective: To review the role of PI3K/AKT/mTOR signalling pathway, and the current and future prospects of targeting PI3Ks for various diseases, like malignant, autoimmune, inflammatory, cardiovascular, neurological disorders etc., laying special emphasis on the inflammatory diseases and associated cellular responses.
Background: Recent findings have publicized phosphoinositide-3-kinases (PI3Ks) as novel therapeutic targets, which are also purported to be involved in the complex pathophysiology of inflammatory and various other diseases. They are recognized to participate in the inflammatory cellular responses by modulating the growth, development and proliferation of various immune cells and hence, affect the release of various cytokines and other inflammatory mediators involved in these manifestations. The recent literature relating this pathway with these diseases is highlighted, with a hope, which remains for the progression of PI3K inhibitors in the market as a treatment option.
Result: With Idelalisib entering the market for cancer, PI3K/AKT signalling has also gained significance as an investigational target for various diseases, particularly for inflammation. Based on the pharmacological, genetic, and clinical data available, PI3K/AKT signalling can be designated as an outstanding target for their treatment.
Conclusion: Further exploration of this pathway may also uncover its involvement in these disorders, which may further contribute to developing the new treatments and can turn out to be an innovative brainwave in the field of experimental and clinical pharmacology in future.
Export Options
About this article
Cite this article as:
Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives, Current Drug Targets 2017; 18 (14) . https://dx.doi.org/10.2174/1389450117666161013115225
DOI https://dx.doi.org/10.2174/1389450117666161013115225 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MEFV Mutation Carriers and Diseases Other than Familial Mediterranean Fever: Proved and Non-Proved Associations; Putative Biological Advantage
Current Drug Targets - Inflammation & Allergy Association between HbA1C (Glycated Hemoglobin) and Clinical Outcomes in Patients with Subarachnoid Hemorrhage After Neuro-intervention
Current Neurovascular Research Congenital Heart Disease: The Crossroads of Genetics, Epigenetics and Environment
Current Genomics Novel Imaging Techniques in Acute Kidney Injury
Current Drug Targets Genetic Determinants of Cerebral Arterial Adaptation to Flow-loading
Current Neurovascular Research Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner?
Current Cardiology Reviews The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
Current Drug Safety Review: Technegas - 99mTc-Metal Core Graphite Nanoparticles for Pulmonary Ventilation Imaging
Current Radiopharmaceuticals Continuous Elevation of Intracellular Ca2+ Is Essential for the Development of Cerebral Vasospasm
Current Vascular Pharmacology Inflammation in Ischemic Stroke: Mechanisms, Consequences and Possible Drug Targets
CNS & Neurological Disorders - Drug Targets A Review on Corrosion Protection of Iron and Steel
Recent Patents on Corrosion Science (Discontinued) Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Recent Patents on Electrospun Biomedical Nanostructures: An Overview
Recent Patents on Biomedical Engineering (Discontinued) Intracranial Non-traumatic Aneurysms in Children and Adolescents
Current Pediatric Reviews Novel Insights into Complex Cardiovascular Pathologies using 4D Flow Analysis by Cardiovascular Magnetic Resonance Imaging
Current Pharmaceutical Design Targeting the Role of Lipoprotein (a) in Stroke
Cardiovascular & Hematological Disorders-Drug Targets Pharmacotherapy of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis
Current Pharmaceutical Design Autophagy after Subarachnoid Hemorrhage: Can Cell Death be Good?
Current Neuropharmacology Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Current Alzheimer Research